Endostatin variations in childhood acute lymphoblastic leukaemia-Comparison with basic fibroblast growth factor and vascular endothelial growth factor

Leukemia Research

Volumn 31, Issue 5, 2007, Pages 629-638

  Schneider, P ^a,b   Vasse, M ^a,c   Corbiere C ^a   Legrand, E ^a   Marie Cardine, A ^a,b   Boquet, C ^c   Cazin, L ^a   Vannier, J P ^a,b  

^a UNIVERSITÉ DE ROUEN   (France)

^b Service d'Hématologie Oncologie Pédiatrique   (France)

^c ROUEN UNIVERSITY HOSPITAL   (France)

Author keywords

Acute lymphoblastic leukaemia; Angiogenesis; Childhood; Endostatin; Microenvironment

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; COLLAGEN TYPE 13; ENDOSTATIN; MESSENGER RNA; VASCULOTROPIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANGIOGENESIS; ARTICLE; CHILD; CHILDHOOD LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; HEPATOMEGALY; HUMAN; HUMAN CELL; INFANT; KARYOTYPE; LEUKEMIA REMISSION; LYMPHOBLAST; PRIORITY JOURNAL; PROGNOSIS; PROTEIN SECRETION;

ADOLESCENT; BLOTTING, WESTERN; CASE-CONTROL STUDIES; CELL PROLIFERATION; CHILD; CHILD, PRESCHOOL; ENDOSTATINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FIBROBLAST GROWTH FACTOR 2; HEPATOMEGALY; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOPHENOTYPING; INFANT; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; LYMPHOCYTES; NEOPLASM RECURRENCE, LOCAL; NEOVASCULARIZATION, PATHOLOGIC; REMISSION INDUCTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34147135971     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2006.08.023     Document Type: Article

References (41)

1. Padro T., Ruiz S., Bieker R., Burger H., Steins M., Kienast J., et al. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood 95 (2000) 2637-2644
2. Perez-Atayde A.R., Sallan S.E., Tedrow U., Connors S., Allred E., and Folkman J. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol 150 (1997) 815-821
3. Aguayo A., Estey E., Kantarjian H., Mansouri T., Gidel C., Keating M., et al. Cellular VEGF is a predictor of outcome in patients with acute myeloblastic leukemia. Blood 94 (1999) 3717-3721
4. Aguayo A., Kantarjian H.M., Estey E.H., Giles F.J., Verstovsek S., Manshouri T., et al. Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes. Cancer 95 (2002) 1923-1930
5. Aref S., Mabed M., Sakrana M., Goda T., and El-Sherbiny M. Soluble hepatocyte growth factor (sHGF) and vascular endothelial growth factor (sVEGF) in adult acute myeloid leukemia: relationship to disease characteristics. Hematology 7 (2002) 273-279
6. Brunner B., Gunsilius E., Schumacher P., Zwierzina H., Gastl G., and Stauder R. Blood levels of angiogenin and vascular endothelial growth factor are elevated in myelodysplastic syndromes and in acute myeloid leukemia. J Hematother Stem Cell Res 11 (2002) 119-125
7. Albitar M. Angiogenesis in acute myeloid leukemia and myelodysplastic syndrome. Acta Haematol 106 (2001) 170-176
8. Yetgin S., Yenicesu I., Cetin M., and Tuncer M. Clinical importance of serum vascular endothelial and basic fibroblast growth factors in children with acute lymphoblastic leukemia. Leuk Lymphoma 42 (2001) 83-88
9. Wellmann S., Guschmann M., Griethe W., Eckert C., von Stackelberg A., Lottaz C., et al. Activation of the HIF pathway in childhood ALL, prognostic implications of VEGF. Leukemia 18 (2004) 926-933
10. Schneider P., Vasse M., Legrand E., Callat M.P., and Vannier J.P. Have urinary levels of the angiogenic factors, basic fibroblast growth factor and vascular endothelial growth factor, a prognostic value in childhood acute lymphoblastic leukaemia. Br J Haematol 122 (2003) 163-164
11. Fiedler W., Mesters R., Tinnefeld H., Loges S., Staib P., Duhrsen U., et al. A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia. Blood 102 (2003) 2763-2767
12. Steins M.B., Bieker R., Padro T., Kessler T., Kienast J., Berdel W.E., et al. Thalidomide for the treatment of acute myeloid leukemia. Leuk Lymphoma 44 (2003) 1489-1493
13. Schuch G., Oliveira-Ferrer L., Loges S., Laack E., Bokemeyer C., Hossfeld D.K., et al. Anti-angiogenic treatment with endostatin inhibits progression of AML in vivo. Leukemia 19 (2005) 1312-1317
14. Wickstrom S.A., Alitalo K., and Keski-Oja J. Endostatin signaling and regulation of endothelial cell-matrix interactions. Adv Cancer Res 94 (2005) 197-229
15. Wen W., Moses M.A., Wiederschain D., Arbiser J.L., and Folkman J. The generation of endostatin is mediated by elastase. Cancer Res 59 (1999) 6052-6056
16. Im E., Venkatakrishnan A., and Kazlauskas A. Cathepsin B regulates the intrinsic angiogenic threshold of endothelial cells. Mol Biol Cell 16 (2005) 3488-3500
17. Bene M.C., Boumsell L., Vannier J.P., Garand R., Solary E., Faure G., et al. Immunologic analysis of a thousand cases of acute leukaemia. French Groupe d'Etude Immunologique des Leucémies (GEIL). Nouv Rev Fr Hematol 31 (1989) 133-136
18. Sbaa-Ketata E., Vasse M., Lenormand B., Schneider P., Soria C., and Vannier J.P. Fibronectin increases the migration induced by stromal cell-derived factor 1 alpha (SDF-1α) in pre-B acute lymphoblastic leukemia cells. Eur Cytokine Netw 12 (2001) 223-230
19. Glenjen N., Mosevoll K.A., and Bruserud O. Serum levels of angiogenin, basic fibroblast growth factor and endostatin in patients receiving intensive chemotherapy for acute myelogenous leukaemia. Int J Cancer 101 (2002) 86-94
20. Vasse M., Pourtau J., Trochon V., Muraine M., Vannier J.P., Lu H., et al. Oncostatin M induces angiogenesis in vitro and in vivo. Arterioscler Thromb Vasc Biol 19 (1999) 1835-1842
21. Ades E.W., Candal F.J., Swerlick R.A., George V.G., Summers S., Bosse D.C., et al. HMEC-1: establishment of an immortalized human microvascular endothelial cell line. J Invest Dermatol 99 (1992) 683-690
22. Saarela J., Ylikarppa R., Rehn M., Purmonen S., and Pihlajaniemi T. Complete primary structure of two variant forms of human type XVIII collagen and tissue-specific differences in the expression of the corresponding transcripts. Matrix Biol 16 (1998) 319-328
23. Feldman A.L., Alexander H.R., Bartlett D.L., Kranda K.C., Miller M.S., Costouros N.G., et al. A prospective analysis of plasma endostatin levels in colorectal cancer patients with liver metastases. Ann Surg Oncol 8 (2001) 741-745
24. Feldman A.L., Tamarkin L., Paciotti G.F., Simpson B.W., Linehan W.M., Yang J.C., et al. Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with stage IV clear cell renal cancer. Clin Cancer Res 6 (2000) 4628-4634
25. Suzuki M., Iizasa T., Ko E., Baba M., Saitoh Y., Shibuya K., et al. Serum endostatin correlates with progression and prognosis of non-small cell lung cancer. Lung Cancer 35 (2002) 29-34
26. Zhao J., Yan F., Ju H., Tang J., and Oin J. Correlation between serum vascular endothelial growth factor and endostatin levels in patients with breast cancer. Cancer Lett 204 (2004) 87-95
27. Guan K.P., Ye H.Y., Yan Z., Wang Y., and Hou S.K. Serum levels of endostatin and matrix metalloproteinase-9 associated with high stage and grade primary transitional cell carcinoma of the bladder. Urology 61 (2003) 719-723
28. Werther K., Christensen I.J., and Nielson H.J. Determination of vascular endothelial growth factor (VEGF) in circulating blood: significance of VEGF in various leucocytes and platelets. Scand J Clin Lab Invest 62 (2002) 343-350
29. Ma L., Hollenberg M.D., and Wallace J.L. Thrombin-induced platelet endostatin release is blocked by a proteinase activated receptor-4 (PAR 4) antagonist. Br J Pharmacol 134 (2001) 701-704
30. Hanai J., Gloy J., Karumanchi S.A., Kale S., Tang J., Hu G., et al. Endostatin is a potential inhibitor of Wnt signaling. J Cell Biol 158 (2002) 529-539
31. Brammer R.D., Bramhall S.R., and Eggo M.C. Endostatin expression in a pancreatic cell line is modulated by a TNFalpha-dependent elastase. Br J Cancer 93 (2005) 1024-1028
32. Schmidt A., Sommer F., Reiner M., Klotz T., Engelmann U., Addicks K., et al. Differential endostatin binding to bladder, prostate and kidney tumour vessels. BJU Int 95 (2005) 174-179
33. Janowska-Wieczorek A., Majka M., Marquez-Curtis L., Wertheim J.A., Turner A.R., and Ratajczak M.Z. Bcr-abl-positive cells secrete angiogenic factors including matrix metalloproteinases and stimulate angiogenesis in vivo in Matrigel implants. Leukemia 16 (2002) 1160-1166
34. Linder-Stragliotto C., Strander H., Munck Wikland E., and Sten-Linder M. Low levels of endostatin in the urine from patients with malignant disease. Tumour Biol 23 (2002) 222-227
35. Shichiri M., and Hirata Y. Antiangiogenesis signals by endostatin. FASEB J 15 (2001) 1044-1053
36. Dkhissi F., Lu H., Soria C., Opolon P., Griscelli F., Liu H., et al. Endostatin exhibits a direct antitumor effect in addition to its anti-angiogenic activity in colon cancer cells. Hum Gene Ther 14 (2003) 997-1008
37. Kay N.E., Bone N.D., Tschumper R.C., Howell K.H., Geyer S.M., Dewald G.W., et al. B-CLL cells are capable of synthesis and secretion of both pro- and anti-angiogenic molecules. Leukemia 16 (2002) 911-919
38. Gora-Tybor J., Blonski J.Z., and Robak T. Circulating proangiogenic cytokines and angiogenesis inhibitor endostatin in untreated patients with chronic lymphocytic leukaemia. Mediators Inflamm 12 (2003) 167-171
39. Bertolini F., Paolucci M., Peccatori F., Cinieri S., Agazzi A., Ferrucci P.F., et al. Angiogenic growth factors and endostatin in non-hodgkin's lymphoma. Br J Haematol 106 (1999) 504-509
40. Bono P., Teerenhovi L., and Joensuu H. Elevated serum endostatin is associated with poor outcome in patients with non-hodgkin lymphoma. Cancer 97 (2003) 2767-2775
41. Urbanska-Rys H., and Robak T. High serum level of endostatin in multiple myeloma at diagnosis but not in the plateau phase after treatment. Mediators Inflamm 12 (2003) 229-235